|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||0.02|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Molecular Partners AG's ( VTX:MOLN ) price-to-sales (or "P/S") ratio of 10.1x might make it look like a sell right now...
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Spare a thought for...
Molecular Partners ( VTX:MOLN ) Full Year 2022 Results Key Financial Results Revenue: CHF189.6m (up by CHF179.8m from...
A look at the shareholders of Molecular Partners AG ( VTX:MOLN ) can tell us which group is most powerful. With 41...
Molecular Partners (VTX:MOLN) has had a great run on the share market with its stock up by a significant 20% over the...
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...